Zobrazeno 1 - 10
of 548
pro vyhledávání: '"Paul A, Murray"'
Autor:
Navta Masand, Tracey A. Perry, Matthew Pugh, Eanna Fennell, Aoife Hennessy, Wenbin Wei, Katerina Bouchalova, David Burns, Pamela Kearns, Graham Taylor, Katerina Vrzalikova, Paul G. Murray
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/631c89ae07104df9a40c03abce5c5c39
Autor:
Nicholas Davies, Tegan Francis, Ceri Oldreive, Maria Azam, Jordan Wilson, Philip J. Byrd, Megan Burley, Archana Sharma-Oates, Peter Keane, Sael Alatawi, Martin R. Higgs, Zbigniew Rudzki, Maha Ibrahim, Tracey Perry, Angelo Agathaggelou, Anne-Marie Hewitt, Edward Smith, Constanze Bonifer, Mark O’Connor, Josep V. Forment, Paul G. Murray, Eanna Fennell, Gemma Kelly, Catherine Chang, Grant S. Stewart, Tatjana Stankovic, Marwan Kwok, Alexander Malcolm Taylor
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations. ATM is also frequently mutated in
Externí odkaz:
https://doaj.org/article/a850f4208cec4de88e6a8aaa3e6fc37b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/43977cced5304171b307d2d5fb09b97a
Autor:
Aisling M. Ross, Ciara I. Leahy, Fiona Neylon, Jana Steigerova, Patrik Flodr, Martina Navratilova, Helena Urbankova, Katerina Vrzalikova, Lucia Mundo, Stefano Lazzi, Lorenzo Leoncini, Matthew Pugh, Paul G. Murray
Publikováno v:
Life, Vol 13, Iss 2, p 521 (2023)
Epstein–Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymp
Externí odkaz:
https://doaj.org/article/f7951fc6c74c43938958ad08ecb24cc1
Autor:
Eleni Syrimi, Eanna Fennell, Alex Richter, Pavle Vrljicak, Richard Stark, Sascha Ott, Paul G. Murray, Eslam Al-Abadi, Ashish Chikermane, Pamela Dawson, Scott Hackett, Deepthi Jyothish, Hari Krishnan Kanthimathinathan, Sean Monaghan, Prasad Nagakumar, Barnaby R. Scholefield, Steven Welch, Naeem Khan, Sian Faustini, Kate Davies, Wioleta M. Zelek, Pamela Kearns, Graham S. Taylor
Publikováno v:
iScience, Vol 24, Iss 11, Pp 103215- (2021)
Summary: Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had h
Externí odkaz:
https://doaj.org/article/cb7ebce799514eb180b30ec967fb855b
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Externí odkaz:
https://doaj.org/article/33df053cfba644b091296af8443afb44
Autor:
Marcus A. Johns, Yongho Bae, Francisco E. G. Guimarães, Evandro M. Lanzoni, Carlos A. R. Costa, Paul M. Murray, Christoph Deneke, Fernando Galembeck, Janet L. Scott, Ram I. Sharma
Publikováno v:
ACS Omega, Vol 3, Iss 1, Pp 937-945 (2018)
Externí odkaz:
https://doaj.org/article/62ab19d30dee42cfbb2989398eefc8b5
Autor:
Lou-Ella M.M. Alexander, January Watters, Jessica A. Reusch, Michelle Maurin, Brook S. Nepon-Sixt, Katerina Vrzalikova, Mark G. Alexandrow, Paul G. Murray, Kenneth L. Wright
Publikováno v:
Data in Brief, Vol 15, Iss , Pp 222-227 (2017)
The data presented here are related to the research article entitled âSelective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survivalâ (Alexander et al., 2017) [1]. The cited research arti
Externí odkaz:
https://doaj.org/article/318227ac38ac4a278d599af9df98bd2d
Autor:
David M. Burns, Gordon B. Ryan, Caroline M. Harvey, Eszter Nagy, Simon Hughes, Paul G. Murray, Nigel H. Russell, Christopher P. Fox, Heather M. Long
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) is a life-threatening complication of T-lymphocyte deplete allogeneic hematopoietic stem cell transplantation (allo-HSCT). For patients with PTLD refractory to Rit
Externí odkaz:
https://doaj.org/article/907bed34adb54dc59ab39d277e93efd3
Autor:
David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert J. Hayashi, Michelle L. Hermiston, Robert D. Annett, J. Hunter Archer, Barbara L. Asselin, Keith J. August, Steve Y. Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I. Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I. Patel, Eric S. Schafer, Tal Schechter, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweidler-McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad77077f78bd85acc4f42ec987b359a
https://pubmed.ncbi.nlm.nih.gov/35271306
https://pubmed.ncbi.nlm.nih.gov/35271306